Dalfampridine – USA

Dalfampridine – USA

On Jan. 04, 2019, Full Federal Circuit denied request of Acorda Therapeutics Inc’s for reconsideration of a decision invalidating Ampyra® multiple sclerosis patents.

Previously on 9/10/18, Federal Circuit affirmed the Delaware district court’s decision which found four patents invalid as obvious (reported here on this blog). In summary, Court concluded that the dosing regimen contained in the claims of the four patents would have been obvious to try considering the prior study designs and also upheld the “blocking patent” analysis.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved